Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

304 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011).
Loh ML, Tasian SK, Rabin KR, Brown P, Magoon D, Reid JM, Chen X, Ahern CH, Weigel BJ, Blaney SM. Loh ML, et al. Pediatr Blood Cancer. 2015 Oct;62(10):1717-24. doi: 10.1002/pbc.25575. Epub 2015 May 13. Pediatr Blood Cancer. 2015. PMID: 25976292 Free PMC article. Clinical Trial.
Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura.
Bennett CM, Rogers ZR, Kinnamon DD, Bussel JB, Mahoney DH, Abshire TC, Sawaf H, Moore TB, Loh ML, Glader BE, McCarthy MC, Mueller BU, Olson TA, Lorenzana AN, Mentzer WC, Buchanan GR, Feldman HA, Neufeld EJ. Bennett CM, et al. Among authors: loh ml. Blood. 2006 Apr 1;107(7):2639-42. doi: 10.1182/blood-2005-08-3518. Epub 2005 Dec 13. Blood. 2006. PMID: 16352811 Free PMC article. Clinical Trial.
One year follow-up of children and adolescents with chronic immune thrombocytopenic purpura (ITP) treated with rituximab.
Mueller BU, Bennett CM, Feldman HA, Bussel JB, Abshire TC, Moore TB, Sawaf H, Loh ML, Rogers ZR, Glader BE, McCarthy MC, Mahoney DH, Olson TA, Feig SA, Lorenzana AN, Mentzer WC, Buchanan GR, Neufeld EJ; Pediatric Rituximab/ITP Study Group; Glaser Pediatric Research Network. Mueller BU, et al. Among authors: loh ml. Pediatr Blood Cancer. 2009 Feb;52(2):259-62. doi: 10.1002/pbc.21757. Pediatr Blood Cancer. 2009. PMID: 18937333 Free PMC article. Clinical Trial.
Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group study.
Chen IM, Harvey RC, Mullighan CG, Gastier-Foster J, Wharton W, Kang H, Borowitz MJ, Camitta BM, Carroll AJ, Devidas M, Pullen DJ, Payne-Turner D, Tasian SK, Reshmi S, Cottrell CE, Reaman GH, Bowman WP, Carroll WL, Loh ML, Winick NJ, Hunger SP, Willman CL. Chen IM, et al. Among authors: loh ml. Blood. 2012 Apr 12;119(15):3512-22. doi: 10.1182/blood-2011-11-394221. Epub 2012 Feb 24. Blood. 2012. PMID: 22368272 Free PMC article.
Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia.
Maude SL, Tasian SK, Vincent T, Hall JW, Sheen C, Roberts KG, Seif AE, Barrett DM, Chen IM, Collins JR, Mullighan CG, Hunger SP, Harvey RC, Willman CL, Fridman JS, Loh ML, Grupp SA, Teachey DT. Maude SL, et al. Among authors: loh ml. Blood. 2012 Oct 25;120(17):3510-8. doi: 10.1182/blood-2012-03-415448. Epub 2012 Sep 6. Blood. 2012. PMID: 22955920 Free PMC article.
304 results